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BACKGROUND: Aggressive fibromatosis (desmoid tumour) is a locally invasive tumour caused by mutations resulting in b-catenin
protein stabilisation. Apc1638N mice are predisposed to developing aggressive fibromatosis tumours, and male mice develop greater
numbers of tumours than female mice, suggesting a role for androgens in this tumour type.
METHODS: Human aggressive fibromatosis tumours were examined for the expression of the androgen receptor, and primary human
tumour cell cultures were treated with testosterone. Orchidectomised Apc1638N mice were investigated for the development of
tumours, and were treated with testosterone to study the effect of tumour formation and the level of b-catenin.
RESULTS: Androgen receptors are universally expressed in human aggressive fibromatosis tumours. Testosterone increased the
proliferation rate and b-catenin protein level in a dose-dependent manner in human aggressive fibromatosis tumours. Orchiectomy
reduced the number and size of tumours that formed in male Apc1638N mice to a similar level as observed in female mice.
Testosterone treatment increased the number of tumours that formed in orchidectomised male mice, and resulted in a marked
increase in b-catenin protein levels.
CONCLUSION: Testosterone regulates b-catenin protein level and proliferation rate in this mesenchymal tumour. This work identifies
the therapeutic use of testosterone blockade in aggressive fibromatosis as an area for further investigation.
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Aggressive fibromatosis (also known as desmoid tumour) is a
locally invasive fibroproliferative neoplasm that causes deformity,
morbidity and occasional mortality due to local effects on vital
structures. This tumour can occur as sporadic lesion or as a
manifestation of the preneoplastic conditions familial infiltrative
fibromatosis or familial adenomatous polyposis. Most cases of
sporadic tumours are associated with somatic mutations in genes
coding for b-catenin or APC, whereas familial cases are associated
with germline mutations in the APC gene (Alman et al, 1997;
Tejpar et al, 1999). Despite differences in specific mutations in
individual cases, all aggressive fibromatosis tumours are char-
acterised by b-catenin protein stabilisation and activation of
b-catenin-mediated TCF-dependent transcriptional activity
(Alman et al, 1997; Cheon et al, 2002).
b-Catenin is an important mediator in the canonical Wnt
signalling pathway. Wnt ligands bind a receptor complex
comprised of a member of a seven-transmembrane-domain
receptor of the frizzled family and an LRP5/6 co-receptor (Bhanot
et al, 1996; Pinson et al, 2000). In the absence of activating Wnt
ligands, b-catenin becomes phosphorylated at serine and threo-
nine sites encoded in exon 3, and the protein is targeted for
ubiquitin-mediated degradation (Rubinfeld et al, 1996; Aberle
et al, 1997). In the presence of an activating ligand, b-catenin is not
phosphorylated at these sites, accumulates in the cytoplasm and
translocates into the nucleus (Daniels and Weis, 2005). Together
with TCF/LEF transcription factors, it regulates the expression of
cell-type specific target genes (Behrens et al, 1996; van de Wetering
et al, 1997).
A role for sex hormones in aggressive fibromatosis is suggested
by data showing that tumours express receptors for sex steroid
hormones (Ishizuka et al, 2006). In addition, male Apc1638N mice,
which express a mutation in the Apc gene similar to that in familial
infiltrating fibromatosis, develop substantially more tumours than
female mice (Smits et al, 1998; Poon et al, 2001a), implicating
androgens in this tumour. Androgens are known to have a role in
the progression of prostate cancer (Gelmann, 2002; Verras and Sun,
2006), in which a crosstalk between the androgen receptor and
canonical Wnt pathways has been identified at several levels in these
signalling pathways (Truica et al, 2000; Feldman and Feldman, 2001;
Balk, 2002; Mulholland et al, 2002; Chesire and Isaacs, 2003). Such a
possibility could also exist in aggressive fibromatosis. Here, we
examine the role of testosterone in aggressive fibromatosis, in both
human tumours and in the Apc1638N mouse.
MATERIALS AND METHODS
Human aggressive fibromatosis tumour samples
Informed consent was obtained for the use of tumour material and
patient data. Patients with musculoskeletal tumours treated at the
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database that includes demographic information and pathology
data. In many cases, cryopreserved tumour tissue is also available.
For preparation of cryopreserved tissues for storage in the tumour
bank, tissues are snap frozen as soon as possible following surgical
excision. In six patients with aggressive fibromatosis tumours, cells
were also collected from the tumours immediately after surgery
to establish primary cell cultures. The cultures were initially
established in DMEM supplemented with 10% fetal bovine serum
and maintained at 371Ci n5 %C O 2 as previously reported (Alman
et al, 1997; Li et al, 1998). Cells were divided when confluent and
experiments were performed only between the first and third
passages. Further experiments were performed in either 2% (low)
or 5% (high) fetal bovine serum.
Testosterone treatment of cell cultures
Before experimental studies, 210
4 cells were seeded overnight in
charcol-treated androgen-free culture media (Clonetech, Mountain
View, CA, USA). Between 0 and 100mgml
1 of dihydrotestosterone
(DHT, Sigma, St Louis, MO, USA) were added to the media the
next day, and cells studied for the effect of testosterone after 24h.
Cells were grown in either 5% or 2% fetal calf serum (high or low
serum). Cell viability was measured using the Trypan Blue dye
exclusion method, with the number of live and dead cell counted in
three culture dishes for each patient sample. Proliferation was
measured using bromodeoxyuridine (BrdU) incorporation with
the BrdU added for a period of 12h before analysis, and apoptosis
measured using the TUNEL assay, as previously reported (Li et al,
2001). The percent BrdU incorporation and number of TUNEL
stained cells were counted over 10 high-powered fields from three
independent culture flasks for each patient sample.
Orchidectomy and testosterone treatment of Apc1638N
mice
Our local animal care committee approved all of the mouse studies.
The generation and phenotype of Apc1638N mice was previously
reported (Smits et al, 1998). Male Apc1638N mice underwent surgical
orchidectomy or a sham procedure at 6 weeks of age. Mice were
divided into four study groups, each containing 12 mice: sham non-
castrated with no treatment; castrated with no treatment; castrated
with vehicle control; and castrated treated with testosterone (Depo-
testotsterone, Pharmacia, Saint-Laurent, QC, Canada) at 50mgp e rg
of body weight. The drug, or carrier, was administered by intra-
muscular injections every 14 days. A smaller cohort of six Apc1638N
mice that underwent orchidectomy, were treated with 20mgp e rgo f
body weight of Depo-testosterone. Mice were examined until they
were 5 months of age. At the time of autopsy, aggressive fibromatosis
tumours and gastrointestinal polyps were scored for number and
volume as previously reported by an observer blinded to the
treatments (Smits et al, 1998; Poon et al, 2001b). Tumours and
normal tissue were collected for protein extraction. A commercially
available testosterone immunoassay (R&D Systems, Minneapolis,
MN, USA) was used to measure the serum testosterone level in the
treated and control mice.
Expression analysis
RNA expression for the androgen receptor was carried out using
real-time RT–PCR using previously reported primers and condi-
tions, using the expression of GAPDH as a loading control (Linja
et al, 2001) using RNA from 24 sporadic aggressive fibromatosis
tumours. We also examined protein lysates from 18 of the human
tumours, of which protein lysates were available for analysis.
Western blotting was carried out using an androgen receptor
antibody (Abcam ab45089, Cambridge, UK) using previously
reported techniques (Lin et al, 2003). An antibody to GAPDH was
used on the same membranes as a loading control (mouse
monoclonal, Upstate Biotechnology, Lake Placid, NY, USA).
Densitometery was performed for the bands using the AlphaEaseFC
software (Alpha Innotech, San Leandro, CA, USA). The level of
expression was compared between samples from male and from
female patients. Western analysis for b-catenin was carried out
using a mouse polyclonal antibody (Upstate Biotechnology), and
Horseradish peroxidase-tagged secondary antibodies and Enhanced
ChemiLuminescence (Amersham, Little Chalfont, UK) were used to
detect hybridisation (Linja et al,2 0 0 1 ) .b-Catenin expression at the
RNA level was also analysed using real-time RT–PCR using
previously reported primers and conditions (Goyal et al,2 0 0 8 ) .
Statistical analysis
The means, standard deviations and 95% confidence intervals were
calculated for each data set. Data in the manuscript are reported as
the mean and ±95% confidence intervals. Studies were performed
in at least triplicates to ensure reproducibility, and data means
compared using the two-tailed t-test as calculated using Microsoft
Excel (Microsoft, Redmond, WA, USA).
RESULTS
Androgen receptors are expressed in aggressive
fibromatosis tumours from both males and females
We examined RNA from 24 aggressive fibromatosis tumours and
protein from 18 of the tumours for expression of the androgen
receptor by real-time RT–PCR or western blot analysis using
previously reported techniques (Linja et al, 2001; Lin et al, 2003).
All of the tumours were sporadic lesions, and half were from
women. We found that all 24 cases expressed the androgen
receptor. There was a significantly higher level of androgen
receptor mRNA level in the tumours from males compared with
tumours from females. Although there was higher mean level of
the androgen receptor protein in male patients, because of the high
level of variability in the protein levels, this did not reach statistical
significance (Figure 1). There was not an obvious correlation
between the level of expression and other clinical characteristic.
Testosterone regulates cell proliferation aggressive
fibromatosis
Despite the knowledge that androgen receptors are expressed in
aggressive fibromatosis tumour cells, it is not known if androgens
have a functional role in this tumour type. Thus, we examined if
testosterone regulates cell behaviour in aggressive fibrmatosis, using
primary cell cultures from six human tumours (three from men and
three from women). Cultures were prepared as previously reported
(Li et al, 1998), and examined in charcol-treated androgen-free
culture media. Between 0 and 100mgml
1 of DHT was added to the
media, and cell viability, proliferation rate, apoptosis rate examined.
There was a dose-dependent increase in the proliferation rate and
number of viable cells with increasing DHT levels in the cell cultures
but no change in number of dead cells or apoptosis rate. This
finding was observed in cells grown in either high or low serum
concentrations, but the relative difference was greater in cells grown
in lower serum concentrations (Figure 2). There was a greater
increase in cell proliferation in cell cultures maintained in low
serum, and there was a greater increase in proliferation in cultures
from male patients than from female patients.
Castrated Apc1638N mice develop fewer and smaller
aggressive fibromatosis tumours
To examine the role of testosterone in vivo, we examined castrated
male Apc1638N mice and compared the tumour phenotype to
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Figure 1 Human aggressive fibromatosis tumours express the androgen receptor. (A) Real-time RT–PCR (RNA) and western analysis (protein) results
show that the androgen receptor is expressed in aggressive fibromatosis tumours from both men and women. At the RNA level, there is a significantly
higher level of expression in tumours from males. Data are given as means and 95% confidence intervals for different concentrations of dihydrotestosterone.
An asterisk above data shows a significant increased level of expression between tumours from males compared with the level of expression from tumours
in females. (B) Representative western blots showing expression of the androgen receptor in aggressive fibromatosis tumours from both men and women,
with a higher level of expression in the tumours from male patients.
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Figure 2 Dihydrotestosterone regulates cell proliferation in aggressive fibromatosis. Data from primary cell cultures of tumours from male patients
(A–D) and female patients (E–H) show that testosterone regulates cell proliferation. (A and E) Number of dead and live cell after dihydrotestosterone
(DHT) treatment. (B, C, F and G) Proliferation rate given as the proportion of cells exhibiting BrDU incorporation, (B and F) data from high serum
conditions and (C and G) data from low serum conditions. (D and H) Apoptosis as detected by the proportion of cells exhibiting positive TUNEL staining.
Data are given as means and 95% confidence intervals for different concentrations of dihydrotestosterone. An asterisk above data shows a statistically
significant difference from control conditions. There was an increase in the number of viable cells and proliferation rate, but no change in number of dead
cells or apoptosis rate with increasing doses of dihydrotestosterone. Proliferation in cell cultures from tumours from both male and female patients are
responsive to dihydrotestosterone, and while there is a trend towards a greater increase in proliferation in tumours from men than from women, this did not
reach statistical significance.
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The number and size of tumours that developed in 5-month-old
castrated Apc1638N mice was significantly reduced and smaller in
volume as compared with sham non-castrated mice (Figure 3).
Interestingly, the number and size of tumours that developed in
male castrated mice is similar to the number that developed in
female mice (8.63±2.25 vs 6.23±2.96 average number of
tumours). In contrast, there was no significant difference in the
number of gastrointestinal polyps that developed in these mice
between the two groups. This data suggest an in vivo role for
androgens in aggressive fibromatosis.
Testosterone regulates the number and size of aggressive
fibromatosis tumours in castrated Apc1638N mice
There are a number of factors that are altered with castration, and
to determine whether testosterone is a major factor contributing to
the development of aggressive fibromatosis, castrated male
Apc1638N mice were administered testosterone to restore serum
levels comparable to that of control mice. We found that treatment
with 50mg per g of body weight of testosterone resulted in a
significant increase in the number of tumours that formed, close to
that of uncastrated mice (Figure 4). An additional cohort of mice
were castrated and treated with a carrier, and there was no
significant difference in the number of tumours that formed
compared with castrated mice alone (6.63±2.16 vs 8.63±2.25).
The average volume per tumour in orchidectomised Apc1638N
mice treated with testosterone was larger than those treated with
carrier (Figure 4), and the average tumour volume in castrated
mice was close to that in female mice (4.14±2.57 vs
4.15±2.08mm
3). Castrated mice treated with 20mg per g of body
weight of testosterone developed a number and volume of tumours
intermediate between the other groups. Plasma testosterone levels
were 398±95pgml
1 (mean±95% confidence interval) in control
mice, 6±6pgml
1 in castrated mice, 362±64 in mice treated with
50mg per g of body weight of testosterone and 178±59pgml
1 in
mice treated with 20mg per g of body weight of testosterone. There
was a significant difference in levels between castrated mice and
mice treated with 20mg per g of body weight of testosterone
compared with control mice (Po0.05), but there was no significant
difference between mice treated with 50mg per g of body weight of
testosterone and control mice. This data show that the effect of
castration in the aggressive fibromatosis phenotype can be rescued
by testosterone.
Testosterone modulates b-catenin levels in aggressive
fibromatosis tumours
To investigate whether b-catenin levels are modulated by
testosterone in tumours in vivo, we studied tumours from
Apc1638N mice. Tumours from castrated mice treated with carrier
or with testosterone were collected for RNA and protein extraction.
Western blot analysis using an antibody against total b-catenin
demonstrated a three-fold increase in the amount of b-catenin in
castrated mice treated with testosterone compared with those
treated with carrier (Figures 5A and B). There was also a
significant increase in b-catenin protein level in tumours from
mice treated with testosterone compared with control mice
(Figure 5C). We then examined the level of b-catenin in the six
primary cell cultures from the human tumours, and found a
dose-dependent increase in b-catenin with higher levels of DHT
(Figures 5D and E).
The frequency of sporadic aggressive fibromatosis is the
same in men and women
Data on all patients treated at the University of Toronto teaching
hospitals are recorded in a patient registry. We reviewed new
patients who had a pathology proven diagnosis of sporadic
aggressive fibromatosis that presented over the 10-year period
from 1999 to 2009. There were 56 male and 48 female patients.
Thus, in our population, there was not a predominance of this
tumour type in either women or men at our institution. As this is
the only regional referral centre for musculoskeletal tumours in
central Ontario, it is unlikely that a bias due to referral patterns
skewed this data.
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Figure 3 Fewer and smaller aggressive fibromatosis tumours develop in
castrated Apc1638N mice. The number and volume of aggressive
fibromatosis tumours in 5-month-old Apc1638N mice. Volume is given
as mean mm
3 per individual tumour. Castrated mice develop a similar
number of tumours as female mice that are also of a similar volume. Data
are given as means and 95% confidence intervals. An asterisk above data
shows a significant difference from castrated male mice.
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Figure 4 Testosterone regulates the size and number of aggressive
fibromatosis tumours in castrated mice. The number and volume of
aggressive fibromatosis tumours in 5-month-old Apc1638N mice. Volume is
given as mean mm
3 per individual tumour. Testosterone treatment brings
the number and volume of tumours that develop close to that of mice that
are not castrated. Data are given as means and 95% confidence intervals for
different concentrations of testosterone. An asterisk above data shows a
significant difference from castrated male mice.
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sDISCUSSION
Although receptors for both female and male sex hormones are
present on aggressive fibromatosis tumours, most studies on the
role of sex hormones in this tumour type focus on oestrogen. We
found an important role for testosterone as a regulator of cell
proliferation in aggressive fibromatosis, in tumours derived from
both men and women. Castration of male Apc1638N mice
substantially reduced the number and size of tumours they
developed, a change that was reversed when the mice were treated
with testosterone, thus showing an in vivo role for androgen
hormones in this tumour type.
Androgens are well known to influence cell behaviour in
prostate cancer, and a role for testosterone in b-catenin signalling
in prostate cancer is suggested by data showing that androgen
receptor activation potentiates Wnt signalling (Schweizer et al,
2008). Although little is known about the role of testosterone in
mesenchymal tumours, androgens are known to affect mesench-
ymal cell development. Androgens promote anabolism in the
musculoskeletal system, repressing adiposity. Studies in rodents
show that the mechanism by which these mesenchymal cell
changes occurs is mediated by cell signalling pathways that alter
their differentiation potential. In mesenchymal multipotent C3H
10T1/2 cells, testosterone promotes nuclear translocation of an
androgen receptor–b-catenin complex, thus showing that
b-catenin activity can be regulated by testosterone in this cell
type. This was also demonstrated in vivo, wherein testosterone
level positively regulated b-catenin transcriptional activity in
normal mesenchymal cells. Indeed, this regulation is thought to
be partially responsible for the observed changes in muscle
behaviour with aging, when testosterone levels decline (Singh et al,
2006, 2009; Gentile et al, 2010). b-Catenin also has an important
role in cutaneous wound repair regulating the number of dermal
fibroblasts present, and thus scar size (Cheon et al, 2005, 2006).
The decrease in skin wound-healing rate in the elderly can be
modulated by testosterone, and is characterised by smaller
numbers of dermal fibroblasts in the wound. This process is also
associated with a decreased level of b-catenin, and testosterone
treatment increases the level of b-catenin in wound repair (Gilliver
et al, 2009). Thus, there is evidence that testosterone regulates cell
behaviour and b-catenin in a variety of mesenchymal cell types.
Our finding that testosterone regulates b-catenin in this mesen-
chymal tumour, suggests that this is a common mechanism in a
variety of normal and pathological mesenchymal cells.
As both oestrogen and testosterone have roles in modulating cell
behaviour in aggressive fibromatosis, it is possible that sex steroid
hormone modulation can be used to treat this tumour type. The
effective use of oestrogen blockade has been reported in this
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Figure 5 Testosterone modulates b-catenin levels in aggressive fibromatosis tumours. Testosterone treatment upregulates b-catenin protein levels in
mouse and human tumours. (A–C) Data from castrated mice; (D–F) data from the human tumour cell cultures. (A) Relative b-catenin protein level
(compared with GAPDH) is given for 10 mouse tumours in each group. Data are given as means and 95% confidence intervals for mice treated with low or
higher dose testosterone or with carrier. (B) A representative western blot for four individual tumours, one from mice from each group, showing that
testosterone regulates b-catenin protein level. (C) Relative b-catenin RNA level (compared with Gapdh), with castrated mice defined at ‘1’ is given for 10
mouse tumours in each group. Data are given as means and 95% confidence intervals for mice treated with low or higher dose testosterone or with carrier.
(D) Relative b-catenin protein level (compared with GAPDH) from the human tumour cell cultures with various levels of testosterone treatment. (E)A
representative western blot for cell cultures from a single tumour treated with different doses of dihydrotestosterone. (F) Relative b-catenin RNA level
(compared with GAPDH), with control cultures defined as ‘1’ is given for the same cell cultures as in D. Data are given as means and 95% confidence intervals
for different concentrations of dihydrotestosterone. An asterisk above data shows a significant difference from control conditions. ‘T’ indicates testosterone
and ‘DHT’ indicates dihydrotestosterone.
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Altomare et al, 2010). A poor outcome with oestrogen blockade in
some aggressive fibromatosis tumours could be related to the role of
testosterone in this tumour type. It may be that effective therapy
based on sex steroid hormone modulation requires blockade of both
oestrogen and testosterone. This is an area for future investigation.
The oestrogen receptors responsiveness in aggressive fibroma-
tosis tumours has been thought to be responsible for a
predominance of this tumour type in females. However, although
some studies suggest a female predominance of this tumour type
(Reitamo et al, 1986; Fallen et al, 2006; Dafford et al, 2007), others
do not (Pignatti et al, 2000; Lefevre et al, 2008; Nieuwenhuis et al,
2008). We found a similar rate in both males and females at our
centre. In addition, studies reporting on larger number of cases
reporting a female predominance show only a relatively mild if any
effect of gender. Thus, oestrogen responsiveness of tumour cells is
unlikely to result in an overwhelming female predominance to the
development of aggressive fibromatosis. This clinical information,
in concert with experimental data suggest that sex steroid
hormones primarily has a predominant role regulating tumour
cell proliferation, rather than in the initiation of tumour
development. This concept is supported by our finding that both
female and male mice develop tumours. The higher level of
expression of the androgen receptor in tumours from male
patients and the greater responsiveness to testosterone in tumours
from men suggests that the larger size of tumours in male mice is
related to this responsiveness. Despite this difference, both
tumours from men and women express the androgen receptor,
and exhibit a proliferative rate that is responsive to testosterone.
Although the mice that develop aggressive fibromatosis tumours
are models for the human disease they do not necessarily
recapitulate every facet of the disease. The more severe phenotype
in male mice than female mice does not seem to be present in
human tumours. Despite this, the Apc1638N mouse remains a
useful animal in which to study signalling pathways involved in
this tumour type in vivo (Poon et al, 2001b), but these differences
highlight the importance of verifying the findings in tissue or cell
cultures from patients.
b-Catenin is involved in a number of cell processes, including
the structure of cell membrane complexes, transcriptional regula-
tion, altering cell proliferation and regulating apoptosis (Heasman
et al, 1994; Sanson et al, 1996; Gumbiner, 2000; Jamora and Fuchs,
2002; Ferenc et al, 2009). In aggressive fibromatosis, it has a
predominant role regulating cell proliferation, an finding sup-
ported by our observation that testosterone levels correlated both
with b-catenin levels and cell proliferation. As aggressive
fibromatosis is a locally invasive tumour, slowing cell proliferation
may be an effective approach to patient management, and our data
raises the potential that testosterone modulation can be used to
achieve this goal.
Our data extend the role of androgens to a mesenchymal
tumour, aggressive fibromatosis. It explains the observation that
male Apc1638N develop larger number of tumours, and suggests
that androgen receptor-blocking agents could serve as a novel
therapeutic approach to aggressive fibromatosis. Perhaps indivi-
dualised therapy based in part on the relative expression of the
specific sex steroid hormone receptor will prove efficacious.
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